还原型谷胱甘肽预防他汀类药物玫乙肝标志物阳性患者肝损害的临床观察

目的观察还原型谷胱甘肽预防他汀类药物致乙肝标志物阳性患者肝损害的临床疗效。方法选取2010年1月一2012年2月给予他汀类药物治疗的164例乙肝标志物阳性患者，将其随机分为治疗组（82例）和对照组（82例）。在应用他汀类药物治疗原发病的同时，对照组采用基础护肝治疗（肌苷、维生素c），治疗组采用还原型谷胱甘肽静脉滴注（1．2g，1次／d）。分别于用药前和用药后12周检测患者肝功能指标。结果对照组患者服用他汀类药物后AI』水平明显高于用药前（P〈0．05）；治疗组ALT水平前后差异无统计学意义（P〉0．05）。且对照组—d岍升高超过正常值上限（ULN）3倍而停药的比例，亦显著高于治疗组（P〈0．05）。结论还原型谷胱甘肽可明显减少他汀类药物致乙肝标志物阳性患者肝损害的发生。

Clinical Observation on Effectiveness of Reduced Glutathione on Preventing Statin-induced Hepatic Damage in Patients Positive for HBV Serological Markers

Objective To observe the clinical efficacy of reduced glutathione(GSH) on prevention of statin-induced hepatic damage in patients positive for HBV serological markers.Methods One hundred and sixty-four patients positive for HBV serological markers received statin therapy from January 2010 to February 2012 were selected to randomly divide into treatment group and control group(each n=82).On the basis of statin therapy for primary disease,the patients of control group were simultaneously given basic liver-protecting therapy(inosine and vitamin C),while the patients of treatment group simultaneously received reduced glutathione 1.2 g,one time intravenous drip each day.Liver functions of the patients were detected before and after 12-week treatment.Results After the treatment,the level of ALT in the patients of control group was significantly higher than before the treatment(P<0.05).No statistically significant difference was found in the level of ALT of treatment group between before and after the treatment(P>0.05).The proportion of ALT level more than 3 times the upper normal limit and resulted in drug withdrawal in control group was significantly higher than that of treatment group(P<0.05).Conclusions Reduced GSH can significantly decline the occurrence of statin-induced hepatic injury in patients positive for HBV serological markers.